EH
CN
Home
Haisco
Group Profile
Subsidiary Profile
Production Base
Production Equipment
Production Capacity
Products
corporate Culture
Enterprise Philosophy
Employee Benefits
Employees
Enterprise Magazine
Contact Us
Product
Narcotic Analgesics
Endocrine System Drugs
Enteral Parenteral Nutrition Drugs
Neuropsychiatric Drugs
Cardiovascular Drugs
Tumor Related Drugs
Drugs For Digestive Liver Disease
Other
Innovative R&D
Innovative R&D
Our Science
Clinical Trial
Platform
Partnership
Investor
Stock Information
Investor Hotline
Contact Us
EH
CN
Haisco
Group Profile
Subsidiary Profile
Production Base
Production Equipment
Production Capacity
Products
corporate Culture
Enterprise Philosophy
Employee Benefits
Employees
Enterprise Magazine
Contact Us
Product
Narcotic Analgesics
Endocrine System Drugs
Enteral Parenteral Nutrition Drugs
Neuropsychiatric Drugs
Cardiovascular Drugs
Tumor Related Drugs
Drugs For Digestive Liver Disease
Other
Innovative R&D
Innovative R&D
Our Science
Clinical Trial
Platform
Partnership
Investor
Stock Information
Investor Hotline
Home
>
Haisco
>
Historical evolution
>
2019
04月02日
2022-01-07 15:18:04
四川海思科制药有限公司投资美国eXIthera公司600万美元，并获得其产品EP-7041（抗凝血和抗血栓）在中国内地的独家许可，期限10年。
Returns
